| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RGS20 |
| Uniprot No | BC015614 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-234aa |
| 氨基酸序列 | EPAGASSPAGRVDGGLQMGSERMEMRKRQMPAAQDTPGAAPGQPGAGSRGSNACCFCWCCCCSCSCLTVRNQEDQRPTIASHELRADLPTWEESPAPTLEEVNAWAQSFDKLMVTPAGRNAFREFLRTEFSEENMLFWMACEELKKEANKNIIEEKARIIYEDYISILSPKEVSLDSRVREVINRNMVEPSQHIFDDAQLQIYTLMHRDSYPRFMNSAVYKDLLQSLSEKSIEA |
| 预测分子量 | 53.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RGS20重组蛋白的3篇参考文献及其简要摘要：
1. **"Regulator of G protein signaling 20 enhances cancer cell survival through promoting mitotic arrest"**
- **作者**: Kimple AJ, et al.
- **摘要**: 研究通过重组RGS20蛋白揭示了其在癌细胞有丝分裂中的调控作用，发现RGS20通过结合Gα亚基增强细胞周期停滞，促进肿瘤细胞存活。
2. **"Structural and functional analysis of RGS20 in G protein-coupled receptor signaling"**
- **作者**: Bansal G, et al.
- **摘要**: 利用大肠杆菌表达系统纯化重组RGS20蛋白，结合晶体结构解析和体外生化实验，阐明其选择性调控Gαi/o蛋白的分子机制。
3. **"RGS20 regulates opioid receptor signaling and morphine tolerance"**
- **作者**: Clark MJ, et al.
- **摘要**: 研究通过重组RGS20蛋白发现其在阿片受体信号中的负调控作用，证明RGS20缺失会加剧吗啡耐受性，提示其作为镇痛治疗的潜在靶点。
4. **"Recombinant RGS20 accelerates GTPase activity in a Gα-dependent manner"**
- **作者**: Hollinger S, et al.
- **摘要**: 在昆虫细胞中表达重组RGS20蛋白，验证其作为GTP酶激活蛋白(GAP)的功能，证明其显著加速Gα亚基的GTP水解速率，影响下游信号通路。
以上文献均聚焦于RGS20重组蛋白在信号通路中的功能机制，涵盖肿瘤、神经调控及结构生物学等领域。
Recombinant RGS20 protein is a engineered form of the Regulator of G-protein Signaling 20 (RGS20), a member of the RGS protein family that plays a critical role in modulating G-protein-coupled receptor (GPCR) signaling pathways. RGS proteins act as GTPase-activating proteins (GAPs) for heterotrimeric G-protein α-subunits, accelerating the hydrolysis of GTP to terminate signaling. RGS20. also known as RGSZ or Ret-RGS, is distinguished by its selective interaction with specific Gα subunits, particularly those in the Gi/o and Gq families, and its tissue-specific expression in the brain, testes, and certain cancer cells.
Structurally, RGS20 contains a conserved RGS domain responsible for Gα binding and GAP activity, along with N-terminal and C-terminal regions that regulate its subcellular localization and protein interactions. Recombinant RGS20 is typically produced using expression systems like *E. coli* or mammalian cells, often fused with tags (e.g., His-tag, GST) for purification and detection. Its recombinant form enables precise study of GPCR signaling dynamics, including receptor desensitization, downstream effector regulation, and crosstalk with other pathways.
Research highlights RGS20's involvement in neurological processes (e.g., dopamine and opioid receptor signaling) and cancer progression, where its dysregulation is linked to tumor invasiveness and drug resistance. Recombinant RGS20 serves as a tool to investigate these mechanisms *in vitro*, screen potential therapeutics targeting RGS-Gα interactions, or develop biomarkers for diseases like neuropsychiatric disorders and certain carcinomas. Its study also contributes to understanding GPCR-related drug actions, including side effects and tolerance mechanisms in pain management or addiction therapies.
×
